Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of ...
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...
The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...
That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...
As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...
Pfizer not only beat expectations last quarter, but also boosted its guidance.
The US Food and Drug Administration intends to remove most black box warnings from products containing estrogen and progestogen. The decision, announced Monday, is part of a campaign to promote wider ...
At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...
The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...
Launching next year, the new CMS Innovation Center initiative—known as the GENEROUS Model—aims to align Medicaid drug prices ...
Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback